Abemaxen 200 mg (Abemaciclib INN)

Targeted CDK4/6 Inhibitor for Advanced Breast Cancer

💊 Pharmacology:

Abemaciclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6, preventing phosphorylation of the retinoblastoma (Rb) protein. This results in cell-cycle arrest at the G1 phase, thereby suppressing cancer cell proliferation and slowing tumor progression.

📌 Indications:

• Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer

• Used in combination with:

  • Aromatase inhibitors

  • Fulvestrant

• May be used as monotherapy in patients previously treated with endocrine therapy

💉 Dosage & Administration:

• Recommended dose: 200 mg orally, as prescribed by the oncologist

• Can be taken with or without food

• Tablets should be swallowed whole

• Dose adjustment may be required based on tolerance and adverse reactions

⚠️ Precautions & Warnings:

• Monitor complete blood count (CBC) regularly

• Liver function tests should be performed periodically

• Diarrhea is common—early management is essential

• Use caution in patients with hepatic impairment

❌ Contraindications:

• Known hypersensitivity to Abemaciclib or any excipients

🤰 Pregnancy & Lactation:

• Contraindicated during pregnancy due to risk of fetal harm

• Breastfeeding should be discontinued during treatment

⚕️ Side Effects:

Common side effects include:

• Diarrhea

• Neutropenia

• Fatigue

• Nausea

• Decreased appetite

• Anemia

• Elevated liver enzymes

🧊 Storage Conditions:

• Store below 30°C

• Keep in a cool, dry place

• Protect from light and moisture

• Keep out of reach of children